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1. INTRODUCTION 
The increase in life expectancy along with the low birth rate of most countries is 
making the world’s older population grow [1]. For this reason we are giving more 
importance to the quality, quantity and safety of the drugs that are prescribed to the 
elderly. Studies in this field have become more important in recent years. 
1.1. POLYPHARMACY 
Polypharmacy is a prevalent problem among the population over  65 years of age and 
has important consequences in the outcome of the patient, who is already suffering 
structural and functional changes, such as a reduction in their the homeostatic 
capacity. And in general their sensitivity to the drugs is increased [2]. This excess of 
medication is associated with problems like adherence to the treatment, interactions 
between drugs and adverse reactions. 
There is no agreement to define the polymedicated patient. The vast majority of the 
definitions use a quantitative point of view, focusing on the number of prescribed 
drugs [3]. It can be also defined qualitatively, so the patient will be assigned different 
degrees of polypharmacy according to the number of drugs they consume [4]. 
However, most of the literature agrees to use the quantitative definition. The most 
commonly used description dictates that the polymedicated patient is the one that 
takes more than 6 medications over a period of time of at least 6 months [5]. 
Aside from the health problems that may arise from the polypharmacy, there is also 
an economic impact, both to the patient and the administration. This is due to greater 
number of consultations, more personal required and the adverse drug effects 
associated with their treatment [6]. 
1.2. POTENTIALLY INAPPROPRIATE PRESCRIPTION 
Recent reviews have pointed out that the problem is not polypharmacy but  
inappropriate prescription, and suggest that this is the problem that must be 
addressed to optimize pharmacotherapy in older people [7-10]. An Irish 2015 study 
claims that polypharmacy is the main factor of exposure to inappropriate 
prescription. However, they point out that physicians are prescribing more 
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appropriately nowadays and despite the marked increase in polypharmacy, 
inappropriate prescription is not growing at an alarming rate [11]. 
A drug is considered adequate when evidence-based medicine supports its use in a 
particular case when it is well tolerated by the majority of patients and its cost-
effective. We must also keep in mind the individual life expectancy of each person 
avoiding this way preventive therapies in patients with and unfavorable shot-term 
prognosis and promote drugs with a good benefit/risk ratio [12].   
Inappropriate prescription of drug includes: medication used when the risk of adverse 
reactions outweights clinical benefit (especially if there is a safer or more effective 
alternative) [13], the omission of indicated drugs in the absence of contraindications 
when the patient has a significant life expectancy, when a drug is given at a 
frequency higher that indicated or when medications that interact between each other 
or with the diseases of the patient are prescribed [14]. This is more common in 
elderly patients [15, 16] and associated with adverse effects [17]. It is significantly 
related to hospitalization, functional impairment, avoidable resource utilization and 
death [18, 19, 20, 21, 22]. 
The health problem this is causing should not be ignored, several studies show that 
17.5% to 23.5% of community-dwelling older adults take at least one drug that could 
be considered inappropriate [23]. The use of these medications can have serious 
consequences for the health of the patients besides being bad for the administration 
too [24]. 
1.3. TOOLS FOR DETECTING INAPPROPIATRE PRECRIPTION 
Different types of tools for analyzing inappropriate prescriptions have been 
developed with the aim of guiding physicians in clinical practice. Some examples of 
them would be STOPP, Beers and Taiwan criteria as well as the EU(7)PIM. Most of 
them conclude that the two with a more balanced profile are the STOPP and Beers’ 
criteria [25]. 
Beers’ criteria were first described in 1991 [26]. They were originally developed to 
detect inappropriate prescriptions in nursing homes of the United States and 
consisted on a list of thirty drugs that should be avoided. In subsequent reviews 
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(1997, 2003 and 2012) new medications were added according to specific 
pathologies. [27]. The last modification was carried out by the American Geriatrics 
Society in 2015, where an interdisciplinary committee of 13 experts met and applied 
the Delphi method [66] to include new drugs. They added new medications, 
incorporated new areas of interactions and graduated the quality of each 
inappropriate prescription based on the level of evidence [28]. 
The STOPP (Screening Tool of Older Person’s Prescriptions) criteria were born in 
Ireland in 2008 and its clinical development was carried out by the European Union 
Geriatric Medicine Society. They describe the most common treatment errors in 
prescriptions of older adults. STOPP criteria are easy to relate to a diagnosis since 
they are grouped by physiological systems and can be integrated into prescription 
computer systems. Unlike Beers’ criteria, STOPP has a list that detects the lack of 
prescription when a medication is potentially indicated (START). Its last revision 
was carried out in 2014 by a committee of 19 experts in geriatrics and geriatric 
pharmacologists of 13 European countries, they used the Delphi method for the 
validation of new norms. Fifteen criteria were excluded because there were not 
enough evidence to support them and 24 were added (12 to STOPP and 12 to 
START) [29]. 
1.4. COMPARISONS BETWEEN BEERS AND STOPP CRITERIA 
Several studies compare both criteria, [30, 31, 32, 33] however the continuous 
reviews of both [28, 29] may the reason why there is limited literature analyzing their 
last two versions. In the United States Beers’ criteria are used frequently to detect 
inappropriate prescription [35, 36] and studies show a clear benefit of their 
application [37]. None the less their efficacy still generates controversy in European 
countries since some of the drugs included are not prescribed or even available in 
these countries [34]. 
Despite the discrepancies, comparisons of different studies show a prevalence of 
inappropriate prescription between 38 and 45% when using the STOPP criteria and 
between 20 and 35% after the application of Beers’ criteria [30, 31, 32, 33, 38]. 
STOPP criteria has been officially translated to several languages [39] which is an 
advantage against Beers’ criteria, where we can find less independent adaptations. 
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An example of such would be a study that excludes some of the drugs not available 
in Europe and includes others with the same profile that are usually administrated in 
this region [40]. Ultimately, we believe that the future lies on the computerization of 
these criteria because it could be helpful for physicians when making clinical 
decisions [41]. 
2. OBJECTIVES 
This investigation studied polypharmacy and its relation to inappropriate 
prescription, with three main objectives: 
1. Get to know the prevalence of potentially inappropriate prescription in patients 
over 65 in a rural area applying STOPP and Beers’ criteria to their chronic 
medication. 
2. Measure the degree of agreement between STOPP (version 2) [Appendix A] and 
Beers (2015 review) [Appendix B] criteria to detect potentially inappropriate 
prescription (PIP) 
3. Determine the association between polypharmacy and PIP. 
3. MATERIALS AND METHODS 
3.1. TYPE OF STUDY 
An observational cross-sectional study. 
3.2. STUDY POPULATION 
This research was carried out in a rural area of A Coruña, located in the northwest of 
Spain. The Health Center is in charge of 12,057 people of which 3,344 are over 65. 
Patients over 99, hospitalized, in palliative care or in nursing homes were excluded 
from the study. 
In order to achieve a precision of 5% in our estimation using a confidence interval of 
95%, assuming that the proportion is 50% it was necessary to include 385 
experimental units in the study, however 34 patients were excluded, so we assume 
that our precision is 5,2%. 
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3.3. SOURCES OF INFORMATION 
Data were collected through electronic medical records using the Galician Health 
Service (SERGAS) IANUS system between January 1 and March 12, 2017. This 
information included gender, age, comorbidities, latest blood tests, other 
complementary studies and active medication. The 351 participants were randomly 
selected from the 3.344 patients of the Health Centre. In this study the polypharmacy 
patient was defined as one who takes six or more drugs for a period of time equal or 
greater than six months [5]. 
A database was made including gender, age, active chronic medication, relevant 
blood tests and chronic pathologies of each patient in order to apply STOPP or 
Beers’ criteria. We only included drugs that the patients bought since IANUS system 
allows to check if the prescribed medication have been dispensed or not.  
In order to detect PIP, STOPP (version 2) [Appendix A] and Beers’ criteria (2015 
review) [Appendix B] were applied. 
3.4. ANALYSIS 
A descriptive analysis about the characteristics of the study population was made, 
distributing by gender, age and number of prescribed chronic medications. STOPP 
and Beers’ criteria were applied and prevalence of PIP was calculated. These were 
only applied to chronic medication, acute medication was not included in this study. 
On the one hand, to measure the degree of agreement between STOPP and Beers’ 
criteria the Cohen kappa index and the intraclass correlation coefficient (ICC) were 
used. To evaluate the K statistic, we followed the classification proposed by Landis 
and Koch [42], which establishes that a K that equals 1 is a perfect agreement, more 
than 0,81 indicates an almost perfect agreement, between 0,61 and 0,80 substantial, 
between 0,41 and 0,60 moderate, between 0,21 and 0,40 fair, between 0, and 0,20 
slight and less than 0 poor. For the interpretation of the ICC we followed the 
classification proposed by Landis and Kock (1977) according to which a ICC that 
equals 1 is a perfect agreement, more than 0,81 indicates an almost perfect 
agreement, between 0,61 and 0,80 substantial, between 0,41 and 0,60 moderate, 
between 0,21 and 0,40 fair, between 0, and 0,20 slight and less than 0 poor 
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On the other hand, in order to calculate the correlation between the number of 
prescribed chronic drugs and PIP, we used the Spearman’s rho coefficient since the 
distribution of the number of medications was very asymmetric. This was interpreted 
by the following classification: a Spearman correlation coefficient of more than 0,75 
indicates a very strong connection, between 0,40 and 0,75 strong, between 0,25 and 
0,40 moderate, between 0,15 and 0,24 weak and less than 0,15 very weak. 
4. RESULTS 
Data were collected from 351 randomized patients of which 207 (59%) were women 
(Table 1). The mean age (interquartile range) was 75 (68-81) and the range of ages 
from 65 to 99. A total of 1252 prescriptions were analyzed and the groups according 
to the quantity of chronic drugs taken were significantly homogenous with the 
highest concentration of patients in the range of 2 to 3 medications, 104 (30%). The 
number of polymedicated patients according to our definition is 81 (23%). 
Table 1. Characteristics of the study population (n=351) 
 Male Female Total 
Number of patients 144 (41%) 207 (59%) 351 
Age distribution (years)    
Median age (IQR) 73 (68-81) 75 (68-81) 75 (68-81) 
65-74 81 (47%) 91 (53%) 172 (49%) 
75-84 42 (33%) 24 (53%) 45 (13%) 
85-94 21 (47%) 24 (53%) 45 (13%) 
+95 0 (0%) 5 (100%) 5 (1%) 
Number of chronic drugs prescribed    
1 or less 32 (41%) 47 (59%) 79 (23%) 
2 to 3 39 (38%) 65 (63%) 104 (30%) 
4 to 5 44 (51%) 43 (49%) 87 (25%) 
More than 6 28 (35%) 53 (65%) 81 (23%) 
IQR = Interquartile range 
4.1. POTENTIALLY INAPPROPRIATE PRESCRIPTIONS 
One hundred and fifty-four STOPP criteria were breached among 34% (n=121) of 
the patients (Table 2). We found 90 patients (25%) with one PIP, 27 (8%) with two 
PIP’s, 2 (0,5%) with three PIP’s and two (0,5%) with four PIP’s. The most common 
PIP’s identified by the STOPP criteria include (i) Drugs that predictably increase the 
risk of falls in older people: Benzodiazepines; (ii) Endocrine system: Sulphonylureas 
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with a long duration of action with type 2 diabetes mellitus; (iii) Analgesic Drugs: 
Use of regular (as distinct from PRN) opioids without concomitant laxative; (iv) 
Drugs that predictably increase the risk of falls in older people: Neuroleptic drugs 
and (v) Analgesic drugs: Long-acting opioids without short-acting opioids for break-
through pain. 
Table 2. Potentially inappropriate prescriptions as determined by STOPP criteria 
Criterion n 
Indication of medication  
 
Any duplicate drug class prescription  4 
Cardiovascular system  
Digoxin for heart failure with normal systolic ventricular function  1 
Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias  1 
Loop diuretic for dependent ankle edema without clinical, biochemical evidence or radiological 
evidence of heart failure, liver failure, nephrotic syndrome or renal failure  
5 
Thiazide diuretic with current significant hypokalaemia, hypercalcaemia or with a history of gout  3 
Antiplatelet/Anticoagulant Drugs  
Long-term aspirin at doses greater than 160mg per day  2 
Aspirin with a past history of peptic ulcer disease without concomitant PPI  2 
NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination  5 
Central Nervous System and Psychotropic Drugs  
Tricyclic Antidepressants (TCAs) with dementia, narrow angle glaucoma, cardiac conduction 
abnormalities, prostatism, or prior history of urinary retention  
1 
Initiation of TriCyclic Antidepressants (TCAs) as first-line antidepressant treatment  2 
Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant 
hyponatraemia  
5 
Antipsychotics in those with parkinsonism or Lewy Body Disease  1 
Levodopa or dopamine agonists for benign essential tremor  5 
First-generation antihistamines  5 
Renal System  
Metformin if eGFR < 30  3 
Gastrointestinal System  
PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic 
dosage for > 8 weeks  
2 
Respiratory System  
Theophylline as monotherapy for COPD  2 
Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in 
moderate-severe COPD  
5 
Musculoskeletal System  
NSAID with severe hypertension or severe heart failure  3 
Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where 
paracetamol has not been tried  
3 
COX-2 selective NSAIDs with concurrent cardiovascular disease  3 
Urogenital System  
Antimuscarinic drugs with dementia, or chronic cognitive impairment, narrow-angle glaucoma 
or chronic prostatism 
4 
Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic hypotension or 
micturition syncope 
1 
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Endocrine System  
Sulphonylureas with a long duration of action with type 2 diabetes mellitus 14 
Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes  3 
Drugs that predictably increase the risk of falls in older people  
Benzodiazepines  42 
Neuroleptic drugs  8 
Hypnotic Z-drugs  3 
Analgesic Drugs  
Use of regular (as distinct from PRN) opioids without concomitant laxative  10 
Long-acting opioids without short-acting opioids for break-through pain 6 
Total 154 
PPI = Proton-pump inhibitor; NSAID = Nonsteroidal anti-inflamatory drug; TCA = Tricyclic antidepressant; SSRI = 
Selective serotonin reuptake inhibitors; GFR = Glomerular filtration rate; COPD = Chronic obstructive pulmonary 
disease 
Beers’ criteria identified 104 PIP’s (Table 3) distributed among 87 patients (25%). 
One PIP was described in 65 patients (19%), two PIP’s in 21 patients (6%) and three 
PIP’s in only one patient. The most common PIP’s identified by Beers’ criteria are (i) 
Benzodiazepines; (ii) Proton-pump inhibitors; (iii) Antipsychotics (first and second 
generation) and (iv) digoxin. 
Table 3. Potentially inappropriate prescriptions described by Beers’ criteria 
Criterion n 
Independent of diagnosis 
 
Hydroxicine 4 
Nitrofurantoin 2 
Doxazosin 2 
Digoxin 5 
Amiodarone 1 
Amitriptyline 3 
Paroxetine 2 
Benzodiazepines 42 
Antipsychotics (first and second generation) 8 
Zolpidem 3 
Metoclopramide 4 
Proton-pump inhibitors 11 
Ibuprofen 3 
Diclofenac 3 
Considering diagnosis  
History of falls  
Benzodiazepines 2 
Congnitive impairment  
Anticholinergics 4 
Drug-drug interactions  
Warfarin – NSAIDs 3 
Kidney malfunction  
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Pregabalin eGFR<60 1 
Tramadol eGFR<30 1 
Ranitidine eGFR<50 1 
Total 105 
 
4.2. INTER-RATER AGREEMENT BETWEEN STOPP AND BEERS’ 
CRITERIA 
STOPP and Beers’ criteria agree in the non-detection of any PIP in 218 patients 
(62%) and in the presence of PIP in 88 patients (25%). STOPP criteria detected more 
PIP which were not matched by Beers’ criteria, 45 patients (15%) versus 14 patients 
(4%). 
Table 4. Frecuency, percentage, Cohen's Kappa coefficient and Intraclass correlation coefficient of STOPP and 
Beers’ criteria 
STOPP/Beers No PIM Presence of PIM Total 
No PIM 218 (62%) 14 (4%) 232 (66%) 
Presence of PIP 45 (13%) 74 (21%) 119 (34%) 
Total 263 (75%) 88 (25%) 351 
K  = 0.60 
ICC = 0.66 
ICC = Intraclass correlation coefficient; K = Cohen’s kappa coefficient 
Cohen’s Kappa coefficient (K) has a value of 0,60 which is in the border of moderate 
and good concordance. Intraclass correlation coefficient’s (ICC) value is 0,63 
indicating a good or substantial agreement. 
4.3. ASSOCIATON BETWEEN POLYPHARMACY AND PIP 
The association between the number of prescribed chronic medications and the 
amount of PIP detected by both criteria show a growing trend (Table 5). An increase 
in the frequency of PIP’s is seen when the number of drugs used increases from 1, 
8% when applying STOPP criteria and 4% utilizing Beers’ criteria to those in 
polypharmacy range that reach a 58%  and 48% of PIP’s for STOPP c Beers’ criteria 
respectively. 
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Table 5. Number and % of PIP detected per patient according to STOPP and Beers’ criteria 
Number of 
chronic 
drugs 
prescribed 
Number (%) of PIP/patient 
STOPP Beers 
0 1 2 or more 0 1 2 or more 
1 or less 73 (92%) 6 (8%) 0 (0%) 76 (96%) 3 (4%) 0 (0%) 
2 to 3 74 (71%) 27 (26%) 3 (3%) 84 (81%) 18 (17%) 2 (2%) 
4 to 5 49 (56%) 29 (33%) 9 (11%) 62 (71%) 18 (21%) 7 (8%) 
More than 6 34 (42%) 28 (35%) 19 (23%) 42 (52%) 26 (32%) 13 (16%) 
Total 230 (65%) 90 (26%) 31 (9%) 264 (75%) 65 (19%) 22 (6%) 
STOPP  Number of drugs – PIP Spearman’s rho = 0.398; p < 0.001 
Beers   Number of drugs – PIP Spearman’s rho = 0.382; p < 0.001   
 
Spearman’s correlation coefficient for the number of medications and the amount of 
PIP is even in both classifications, for STOPP criteria it has a value of 0.398 and for 
Beers’ criteria the value is 0.382, both being significant results (*** p<0.001) . This 
means a connection at the border between moderate and strong. 
This increasing trend of PIP associated with the number of chronic drugs prescribed 
can be visualized in Fig. 1. 
Figure 1. Association of the number of drugs prescribed with the number of PIP detected according to STOPP 
and Beers’ criteria 
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5. DISCUSSION 
Potentially inappropriate prescription is a serious problem that mainly affects the 
elderly. In our analysis a PIP rate of 34 and 25% according to STOPP and Beers’ 
criteria respectively was detected among community-dwelling old adults. Other 
European studies show very similar data finding the range of detection of PIP 
according to STOPP between 35 and 42% and 25 to 28% for Beers’ criteria [33,43]. 
In American literature these factors are even higher [44,45]. 
Concerns about the application of Beers’ criteria to the European territory have been 
reinforced by this study [16, 46, 47]. Twenty seven percent of the drugs included in 
these criteria are not even commercialized in Spain, new active principles should also 
be added in order to improve their application [40]. Also, the designation of certain 
prescriptions might be inadequate, such as the prescription of amiodarone and 
doxazosin in older people regardless of the diagnosis [48]. Amiodarone may be the 
only effective agent for the control of arrhythmias and, even though it is not the first 
line of treatment, in particular cases its use is appropriate. Doxazosin is suitable in 
patients with resistant hypertension. In the present study, the three cases related to 
these prescriptions were justified. 
Both criteria have a good degree of agreement, this has been reflected our results 
where 60% of the PIP detected by Beers could also be found by the STOPP criteria. 
This is mainly related to the detection of benzodiazepines and neuroleptics as 
potentially inappropriate prescription by both criteria. Both drugs represent a 48% of 
detected STOPP criteria and a 32% of Beer’s criteria. 
The high percentage of the PIP’s detected related to benzodiazepines is a significant 
problem in Spain, where even the non-specialized literature has noticed. Its 
consumption is four times higher than other European countries, and it even exceeds 
the US consumption [49, 50]. In our study, according to STOPP they represent the 
27% of all PIP’s and for Beers’ criteria a 40%. They have been described as 
inappropriate mainly due to their increased risk of falls and fractures and their 
contribution to mental deterioration [51, 52]. They have also been identified as the 
most common cause of potential problems in older people [53, 54, 55, 56] and their 
chronic use, which is more prevalent in females, has been described in more than 
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30% of women over 65. They represent an avoidable risk to the health of these 
patients and there are multiple pharmacological and non-pharmacological 
alternatives available to treat insomnia and anxiety [57], which are the main causes 
of their prescription. 
The medical community is aware of the problem that benzodiazepines present in 
Spain however their prescription is prevalent, so we think that the true potential of 
these two tools is actually in the least prevalent criteria. Often these occur due to an 
error of the prescriber and/or because they are not known by the physician to be 
PIPs. Studies show that the contribution of a pharmacist can help to improve 
medication management in older patients and improve patient outcomes [58, 59, 60]. 
By simply applying these criteria most of the PIP’s detected in this study would have 
been avoided easily. 
Our results, like other previous studies [61,62] show that a higher number of chronic 
medications prescribed was associated with more inappropriate prescriptions 
reaching a prevalence of PIP around 50% according to both criteria. Polypharmacy is 
increasingly affecting older people and physicians justify it because of the complex 
comorbidity of these patients. A strong association has been described between 
polypharmacy and its negative clinical consequences in primary care [31, 63]. It is a 
health problem that leads to a greater number of adverse reactions and higher costs 
and therefore affects both the patient and the administration. Managing the patient’s 
prescriptions in order to reduce the number of medications taken should be a priority 
in those patients using more than 6 drugs. This would reduce the number of 
potentially inappropriate medications significantly. 
It is important to note that the lack of information in the medical records can be 
considered a limitation when applying the criteria, where some of the potentially 
inappropriate prescriptions may have been overestimated or underestimated. It 
should be kept in mind that the data have been collected and interpreted by a single 
person and that the detection of a PIP using these criteria cannot be considered a real 
problem until the clinical judgment of the prescriber is considered, according to the 
individual situation of each patient. 
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A practical solution for inappropriate prescribing has no yet been established, 
however the direction taken in recent years are improving the quality of the 
medication in elderly patients. Last year an IT tool called TRIM (Tool to Reduce 
Inappropriate Medications) was developed, it is based in an algorithm that uses both 
criteria analyzed in this study and it has shown promising results significantly 
reducing the amount of PIP [64, 65]. We believe that the future lies on this kind of 
approaches, creating a standard based on the existing literature including both of the 
criteria we have used here and others, such as the Taiwan criteria or the EU(7)PIM, 
and integrate it into a computer model. On top of this we think the contribution of the 
pharmacists is also needed since they are often in charge of alerting the physician to 
consider whether a medication is the possible cause of a negative result in the 
patient’s health. Also they are in charge of programs that aim to reduce the amount 
of medication patients take. 
6. CONCLUSION 
The application of both the STOPP and Beers’ criteria in our study has shown that 
we are facing a truly prevalent problem among the community-dwelling elderly 
patients. STOPP criteria detected a greater amount of PIP than Beer’s criteria, 
however their agreement is consistent. In order to reduce the number of potentially 
inappropriate prescriptions physicians should reduce the number of polymedicated 
patients, which represent a large percentage of the PIP detected and develop standard 
computerized models that will help detect these inappropriate prescriptions in an 
automated way reducing the chance of errors. 
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APPENDIX 
APPENDIX A. SCREENING TOOL OF OLDER PERSONS’ 
PRESCRIPTIONS (STOPP) VERSION 2. 
TABLE A. STOPP CRITERIA 
 
SECTION A. INDICATION OF MEDICATION  
1. Any drug prescribed without an evidence-based clinical indication.  
2. Any drug prescribed beyond the recommended duration, where treatment duration is well defined.  
3. Any duplicate drug class prescription e.g. Two concurrent NSAIDs, SSRIS, loop diuretics, ACE inhibitors, 
anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to 
considering a new agent).  
 
SECTION B. CARDIOVASCULAR SYSTEM 
1. Digoxin for heart failure with normal systolic ventricular function (no clear evidence of benefit).  
2. Verapamil or diltiazem with NYHA class iii or iv heart failure (may worsen heart failure).  
3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block).  
4. Beta blocker with bradycardia (< 50/min), type ii heart block or complete heart block (risk of complete heart 
block, asystole).  
5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk of side-
effects than beta-blockers, digoxin, verapamil or diltiazem).  
6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available).  
7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of 
heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery 
usually more appropriate).  
8. Thiazide diuretic with current significant hypokalaemia (i.e. Serum K+ < 3.0 mmol/l), hyponatraemia (i.e. 
Serum Na+ < 130 mmol/l) hypercalcaemia (i.e. Corrected serum calcium > 2.65 mmol/l) or with a history of 
gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic).  
9. Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may exacerbate 
incontinence).  
10. Centrally-acting antihypertensives (e.g. Methyldopa, clonidine, moxonidine, rilmenidine, guanfacine), 
unless clear intolerance of, or lack of efficacy with, other classes of antihypertensives (centrally-active 
antihypertensives are generally less well tolerated by older people than younger people).  
11. ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia.  
12. Aldosterone antagonists (e.g. Spironolactone, eplerenone) with concurrent potassium-conserving drugs 
(e.g. ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum potassium (risk of dangerous 
hyperkalaemia i.e. > 6.0 mmol/l – serum k should be monitored regularly, i.e. At least every 6 months).  
13. Phosphodiesterase type-5 inhibitors (e.g. Sildenafil, tadalafil, vardenafil) in severe heart failure 
characterised by hypotension i.e. Systolic BP < 90 mmhg, or concurrent nitrate therapy for angina (risk of 
cardiovascular collapse).  
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SECTION C. ANTIPLATELET/ANTICOAGULANT DRUGS  
1. Long-term aspirin at doses greater than 160mg per day (increased risk of bleeding, no evidence for 
increased efficacy).  
2. Aspirin with a past history of peptic ulcer disease without concomitant PPI (risk of recurrent peptic ulcer).  
3. Aspirin, clopidogrel, dipyridamole, vitamin k antagonists, direct thrombin inhibitors or factor Xa inhibitors 
with concurrent significant bleeding risk, i.e. Uncontrolled severe hypertension, bleeding diathesis, recent non-
trivial spontaneous bleeding) (high risk of bleeding).  
4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary stent(s) inserted 
in the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid 
arterial stenosis (no evidence of added benefit over clopidogrel monotherapy).  
5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients 
with chronic atrial fibrillation (no added benefit from aspirin)  
6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with 
stable coronary, cerebrovascular or peripheral arterial disease (no added benefit from dual therapy).  
7. Ticlopidine in any circumstances (clopidogrel and prasugrel have similar efficacy, stronger evidence and 
fewer side-effects).  
8. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous thrombosis 
without continuing provoking risk factors (e.g. Thrombophilia) for > 6 months, (no proven added benefit).  
9. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary embolus without 
continuing provoking risk factors (e.g. Thrombophilia) for > 12 months (no proven added benefit).  
10. NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination (risk of 
major gastrointestinal bleeding).  
11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased risk of peptic ulcer 
disease).  
 
SECTION D. CENTRAL NERVOUS SYSTEM AND PSYCHOTROPIC DRUGS  
1. Tricyclic antidepressants (TCAs) with dementia, narrow angle glaucoma, cardiac conduction abnormalities, 
prostatism, or prior history of urinary retention (risk of worsening these conditions).  
2. Initiation of Tricyclic antidepressants (TCAs) as first-line antidepressant treatment (higher risk of adverse 
drug reactions with TCAs than with SSRIs or SNRIs).  
3. Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects (chlorpromazine, clozapine, 
flupenthixol, fluphenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous 
urinary retention (high risk of urinary retention).  
4. Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant hyponatraemia i.e. Serum 
Na+ < 130 mmol/l (risk of exacerbating or precipitating hyponatraemia).  
5. Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, 
impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn gradually if taken for 
more than 4 weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped abruptly).  
6. Antipsychotics (i.e. Other than quetiapine or clozapine) in those with parkinsonism or Lewy Body Disease 
(risk of severe extra-pyramidal symptoms).  
7. Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of neuroleptic medications (risk of 
anticholinergic toxicity),  
8. Anticholinergics/antimuscarinics in patients with delirium or dementia (risk of exacerbation of cognitive 
impairment).  
9. Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of dementia (BPSD) 
unless symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke).  
10. Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, 
hypotension, extra-pyramidal side effects, falls).  
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11. Acetylcholinesterase inhibitors with a known history of persistent bradycardia (< 60 beats/min.), heart 
block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as 
beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury).  
12. Phenothiazines as first-line treatment, since safer and more efficacious alternatives exist (phenothiazines 
are sedative, have significant anti-muscarinic toxicity in older people, with the exception of prochlorperazine 
for nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an 
anti-emetic in palliative care).  
13. Levodopa or dopamine agonists for benign essential tremor (no evidence of efficacy)  
14. First-generation antihistamines (safer, less toxic antihistamines now widely available).  
 
SECTION E. RENAL SYSTEM 
1. Digoxin at a long-term dose greater than 125μg/day if eGFR < 30 ml/min/1.73m2 (risk of digoxin toxicity if 
plasma levels not measured).  
2. Direct thrombin inhibitors (e.g. Dabigatran) if eGFR < 30 ml/min/1.73m2 (risk of bleeding).  
3. Factor Xa inhibitors (e.g. Rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 (risk of bleeding).  
4. NSAID’s if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal function).  
5. Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity).  
6. Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis).  
 
SECTION F. GASTROINTESTINAL SYSTEM  
1. Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating parkinsonian symptoms).  
2. PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 
weeks (dose reduction or earlier discontinuation indicated).  
3. Drugs likely to cause constipation (e.g. Antimuscarinic/anticholinergic drugs, oral iron, opioids, verapamil, 
aluminium antacids) in patients with chronic constipation where non-constipating alternatives are available 
(risk of exacerbation of constipation).  
4. Oral elemental iron doses greater than 200 mg daily (e.g. Ferrous fumarate> 600 mg/day, ferrous sulphate 
> 600 mg/day, ferrous gluconate> 1800 mg/day; no evidence of enhanced iron absorption above these 
doses).  
 
SECTION G. RESPIRATORY SYSTEM  
1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of adverse effects due to 
narrow therapeutic index).  
2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe 
COPD (unnecessary exposure to long-term side-effects of systemic corticosteroids and effective inhaled 
therapies are available).  
3. Anti-muscarinic bronchodilators (e.g. Ipratropium, tiotropium) with a history of narrow angle glaucoma (may 
exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention).  
4. Non-selective beta-blocker (whether oral or topical for glaucoma) with a history of asthma requiring 
treatment (risk of increased bronchospasm).  
5. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa (risk of 
exacerbation of respiratory failure).  
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SECTION H. MUSCULOSKELETAL SYSTEM  
1. Non-steroidal anti-inflammatory drug (NSAID) other than COX-2 selective agents with history of peptic ulcer 
disease or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist (risk of peptic ulcer relapse).  
2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart failure (risk of 
exacerbation of heart failure).  
3. Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where paracetamol has not 
been tried (simple analgesics preferable and usually as effective for pain relief).  
4. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthrtitis (risk of systemic 
corticosteroid side-effects).  
5. Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for osteoarthritis (risk of 
systemic corticosteroid side-effects).  
6. Long-term NSAID or colchicine (>3 months) for chronic treatment of gout where there is no contraindication 
to a xanthine-oxidase inhibitor (e.g. Allopurinol, febuxostat) (xanthine-oxidase inhibitors are first choice 
prophylactic drugs in gout).  
7. COX-2 selective NSAIDs with concurrent cardiovascular disease (increased risk of myocardial infarction 
and stroke).  
8. NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of peptic ulcer disease).  
9. Oral bisphosphonates in patients with a current or recent history of upper gastrointestinal disease i.e. 
Dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk 
of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture).  
 
SECTION I. UROGENITAL SYSTEM  
1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of increased confusion, agitation) 
or narrow-angle glaucoma (risk of acute exacerbation of glaucoma), or chronic prostatism (risk of urinary 
retention).  
2. Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic hypotension or micturition 
syncope (risk of precipitating recurrent syncope).  
 
SECTION J. ENDOCRINE SYSTEM  
1. Sulphonylureas with a long duration of action (e.g. Glibenclamide, chlorpropamide, glimepiride) with type 2 
diabetes mellitus (risk of prolonged hypoglycaemia).  
2. Thiazolidenediones (e.g. Rosiglitazone, pioglitazone) in patients with heart failure (risk of exacerbation of 
heart failure).  
3. Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of suppressing 
hypoglycaemic symptoms).  
4. Oestrogens with a history of breast cancer or venous thromboembolism (increased risk of recurrence).  
5. Oral oestrogens without progestogen in patients with intact uterus (risk of endometrial cancer).  
6. Androgens (male sex hormones) in the absence of primary or secondary hypogonadism (risk of androgen 
toxicity; no proven benefit outside of the hypogonadism indication).  
 
SECTION K. DRUGS THAT PREDICTABLY INCREASE THE RISK OF FALLS IN OLDER PEOPLE  
1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance).  
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2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism).  
3. Vasodilator drugs (e.g. Alpha-1 receptor blockers, calcium channel blockers, long-acting nitrates, ACE 
inhibitors, angiotensin I receptor blockers) with persistent postural hypotension i.e. Recurrent drop in systolic 
blood pressure ≥ 20mmhg (risk of syncope, falls).  
4. Hypnotic Z-drugs e.g. Zopiclone, zolpidem, zaleplon (may cause protracted daytime sedation, ataxia).  
 
SECTION L. ANALGESIC DRUGS  
1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, 
methadone, tramadol, pethidine, pentazocine) as first line therapy for mild pain (WHO analgesic ladder not 
observed).  
2. Use of regular (as distinct from PRN) opioids without concomitant laxative (risk of severe constipation).  
3. Long-acting opioids without short-acting opioids for break-through pain (risk of persistence of severe pain).  
 
SECTION N. ANTIMUSCARINIC/ANTICHOLINERGIC DRUG BURDEN  
1. Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (e.g. Bladder 
antispasmodics, intestinal antispasmodics, tricyclic antidepressants, first generation antihistamines) (risk of 
increased antimuscarinic/anticholinergic toxicity). 
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APPENDIX B. 2015 AMERICAN GERIATRICS SOCIETY BEERS 
CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATION USE IN 
OLDER ADULTS 
TABLE B. BEERS’ CRITERIA 
TABLE B1. INDEPENDENT OF DIAGNOSIS 
Anticholinergics 
First-generation antihistamines 
Brompheniramine 
Carbinoxamine 
Chlorpheniramine 
Clemastine 
Cyproheptadine 
Dexbrompheniramine 
Dexchlorpheniramine 
Dimenhydrinate 
Diphenhydramine (oral) 
Doxylamine 
Hydroxyzine 
Meclizine 
Promethazine 
Triprolidine 
Antiparkinsonian agents 
Benztropine (oral) 
Trihexyphenidyl 
Antispasmodics 
Atropine (excludes ophthalmic) 
Belladonna alkaloids 
Clidinium-chlordiazepoxide 
Dicyclomine 
Hyoscyamine 
Propantheline 
Scopolamine 
Antithrombotics 
Dipyridamole, oral short-acting (does not apply to the extended release combination with aspirin) 
Ticlopidine 
Anti-infective 
Nitrofurantoin 
Cardiovascular 
Peripheral alpha-1 blockers 
Doxazosin 
Prazosin 
Terazosin 
Central alpha blockers 
Clonidine 
Guanabenz 
Guanfacine 
Methyldopa 
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Reserpine (>0.1 mg/d) 
Disopyramide 
Dronedarone 
Digoxin 
Nifedipine, immediate release 
Amiodarone 
Central nervous system 
Antidepressants, alone or in combination 
Amitriptyline 
Amoxapine 
Clomipramine 
Desipramine 
Doxepin >6 mg/d 
Imipramine 
Nortriptyline 
Paroxetine 
Protriptyline 
Trimipramine 
Antipsychotics, first- (conventional) and second- (atypical) generation 
Barbiturates 
Amobarbital 
Butabarbital 
Butalbital 
Mephobarbital 
Pentobarbital 
Phenobarbital 
Secobarbital 
Benzodiazepines 
Short- and intermediate- acting 
Alprazolam 
Estazolam 
Lorazepam 
Oxazepam 
Temazepam 
Triazolam 
Long-acting 
Clorazepate 
Chlordiazepoxide (alone or in combination with amitriptyline or clidinium) 
Clonazepam 
Diazepam 
Flurazepam 
Quazepam 
Meprobamate 
Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics 
Eszopiclone 
Zolpidem 
Zaleplon 
Ergoloid mesylates (dehydrogenated ergot alkaloids) isoxsuprine 
Endocrine 
Androgens 
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Methyltestosterone 
Testosterone 
Desiccated thyroid 
Estrogens with or without progestins 
Growth hormone 
Insulin, sliding scale 
Megestrol 
Sulfonylureas, long-duration 
Chlorpropamide 
Glyburide 
Gastrointestinal 
Metoclopramide 
Mineral oil, given orally 
Proton-pump inhibitors 
Pain medications 
Meperidine 
Non-cyclooxygenase-selective 
NSAIDs, oral: 
Aspirin >325 mg/d diclofenac 
Diflunisal 
Etodolac 
Fenoprofen 
Ibuprofen 
Ketoprofen 
Meclofenamate 
Mefenamic acid 
Meloxicam 
Nabumetone 
Naproxen 
Oxaprozin 
Piroxicam 
Sulindac 
Tolmetin 
Indomethacin 
Ketorolac, includes parenteral 
Pentazocine 
Skeletal muscle relaxants 
Carisoprodol 
Chlorzoxazone 
Cyclobenzaprine 
Metaxalone 
Methocarbamol 
Orphenadrine 
Genitourinary 
Desmopressin 
NSAID = nonsteroidal anti-inflammatory drug. 
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TABLE B2. CONSIDERING DIAGNOSIS 
CARDIOVASCULAR 
Heart failure 
NSAIDs and COX-2 inhibitors 
Nondihydropyridine CCBs (diltiazem, verapamil) —avoid only for heart failure with reduced ejection 
fraction 
Thiazolidinediones (pioglitazone, rosiglitazone) 
Cilostazol 
Dronedarone (severe or recently decompensated heart failure) 
Syncope 
Acheis 
Peripheral alpha-1 blockers 
Doxazosin 
Prazosin 
Terazosin 
Tertiary TCAs 
Chlorpromazine 
Thioridazine 
Olanzapine 
CENTRAL NERVOUS SYSTEM 
Chronic seizures or epilepsy 
Bupropion 
Chlorpromazine 
Clozapine 
Maprotiline 
Olanzapine 
Thioridazine 
Thiothixene 
Tramadol 
Delirium 
Anticholinergics (see table B5 for full list) 
Antipsychotics 
Benzodiazepines 
Chlorpromazine 
Corticosteroids 
H2-receptor antagonists 
Cimetidine 
Famotidine 
Nizatidine 
Ranitidine 
Meperidine 
Sedative hypnotics 
Dementia or cognitive impairment 
Anticholinergics (see table 7 for full list) 
Benzodiazepines 
H2-receptor antagonists 
Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics 
Eszopiclone 
Zolpidem 
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Zaleplon 
Antipsychotics, chronic and as-needed use 
 
History of falls or fractures 
Anticonvulsants 
Antipsychotics 
Benzodiazepines 
Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics 
Eszopiclone 
Zaleplon 
Zolpidem 
TCAs 
SSRIs 
Opioids 
Insomnia 
Oral decongestants 
Pseudoephedrine 
Phenylephrine 
Stimulants 
Amphetamine 
Armodafinil 
Methylphenidate 
Modafinil 
Theobromines 
Theophylline 
Caffeine 
Parkinson disease 
All antipsychotics (except aripiprazole, quetiapine, clozapine) 
Antiemetics 
Metoclopramide 
Prochlorperazine 
Promethazine 
GASTROINTESTINAL 
History of gastric or duodenal ulcers 
Aspirin (>325 mg/d) 
Non-COX-2 selective NSAIDs 
KIDNEY AND URINARY TRACT 
Chronic kidney disease stages IV or less (creatinine clearance <30 ml/min) 
NSAIDs (non-cox and cox-selective, oral and parenteral) 
Urinary incontinence (all types) in women 
Estrogen oral and transdermal (excludes intravaginal estrogen) 
Peripheral alpha-1 blockers 
Doxazosin 
Prazosin 
Terazosin 
Lower urinary tract symptoms, benign prostatic hyperplasia 
Strongly anticholinergic drugs, except antimuscarinics for urinary incontinence (table B5) 
CCB = Calcium channel blocker; TCA = Tricyclic antidepressant; SSRI = Selective serotonin reuptake inhibitor. 
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TABLE B3. POTENTIALLY CLINICALLY IMPORTANT NON-ANTI-INFECTIVE DRUG–DRUG INTERACTIONS 
THAT SHOULD BE AVOIDED IN OLDER ADULTS 
ACEIs 
Amiloride or triamterene 
Anticholinergic Anticholinergic 
Antidepressants (i.e., TCAs and SSRIs) ≥2 other CNS-active drugsa 
Antipsychotics ≥2 other CNS-active drugsa 
Benzodiazepines and nonbenzodiazepine, 
Benzodiazepine receptor agonist hypnotics 
≥2 other CNS-active drugsa 
Corticosteroids, oral or parenteral NSAIDs 
Lithium ACEIs  
Lithium Loop diuretics  
Opioid receptor agonist analgesics ≥2 other CNS-active drugsa  
Peripheral Alpha-1 blockers Loop diuretics  
Theophylline Cimetidine  
Warfarin Amiodarone  
Warfarin NSAIDs  
a Central nervous system (CNS)-active drugs: antipsychotics; benzodiazepines; nonbenzodiazepine, 
benzodiazepine receptor agonist hypnotics; tricyclic antidepressants (TCAs); selective serotonin reuptake 
inhibitors (SSRIs); and opioids. 
ACEI = angiotensin-converting enzyme inhibitor. 
TABLE B4. NON-ANTI-INFECTIVE MEDICATIONS THAT SHOULD BE AVOIDED OR HAVE THEIR DOSAGE 
REDUCED WITH VARYING LEVELS OF KIDNEY FUNCTION IN OLDER ADULTS 
Cardiovascular or hemostasis 
Amiloride <30 
Apixaban <25 
Dabigatran <30 
Edoxaban 30–50 
 <30 or >95 
Enoxaparin <30 
Fondaparinux <30 
Rivaroxaban 30–50 
 <30 
Spironolactone <30 
Triamterene <30 
Central nervous system and analgesics 
Duloxetine <30 
Gabapentin <60 
Levetiracetam ≤80 
Pregabalin <60 
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Tramadol <30 
Gastrointestinal 
Cimetidine <50 
Famotidine <50 
Nizatidine <50 
Ranitidine <50 
Hyperuricemia 
Colchicine <30 
Probenecid <30 
TABLE B5. DRUGS WITH STRONG ANTICHOLINERGIC PROPERTIES 
Antihistamines 
Brompheniramine 
Carbinoxamine 
Chlorpheniramine 
Clemastine 
Cyproheptadine 
Dexbrompheniramine 
Dexchlorpheniramine 
Dimenhydrinate 
Diphenhydramine 
(oral) 
Doxylamine 
Hydroxyzine 
Meclizine 
Triprolidine 
Antiparkinsonian agents 
Benztropine 
Trihexyphenidyl 
Skeletal muscle relaxants 
Cyclobenzaprine 
Orphenadrine 
Antidepressants 
Amitriptyline 
Amoxapine 
Clomipramine 
Desipramine 
Doxepin (>6 mg) 
Imipramine 
Nortriptyline 
Paroxetine 
Protriptyline 
Trimipramine 
Antipsychotics 
Chlorpromazine 
Clozapine 
Loxapine 
Olanzapine 
Perphenazine 
Thioridazine 
Trifluoperazine 
Antiarrhythmic 
Disopyramide 
Antimuscarinics (urinary 
incontinence) 
Darifenacin 
Fesoterodine 
Flavoxate 
Oxybutynin 
Solifenacin 
Tolterodine 
Trospium 
Antispasmodics 
Atropine (excludes ophthalmic) 
Belladonna 
alkaloids 
Clidiniumchlordiazepoxide 
Dicyclomine 
Homatropine 
(excludes ophthalmic) 
Hyoscyamine 
Propantheline 
 
Antiemetic 
Prochlorperazine 
Promethazine 
  
 
